AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11911994 — intervention group
Group type: COMPARATOR
Intervention: GTN alone
Number of subjects: 40
Study 9391198 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 82
Study 9391198 — intervention group
Group type: COMPARATOR
Intervention: Conventional appendectomy (CA)
Number of subjects: 82
Study 8903900 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchopulmonary dysplasia (BPD)
Number of subjects: 24
Study 8903900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-term (PT)
Number of subjects: 24
Study 8903900 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD boys
Number of subjects: 24
Study 1708910 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-Bleo
Number of subjects: 83
Study 1708910 — intervention group
Group type: COMPARATOR
Intervention: m-BACOD
Number of subjects: 83
Study 7432958 — intervention group
Group type: EXPERIMENTAL
Intervention: Process Association Tests of Addiction
Number of subjects: 47
Study 31160237 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib (56 mg/m2) and Dexamethasone (Kd56)
Number of subjects: 0
Study 31160237 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib and Dexamethasone (Vd)
Number of subjects: 0
Study 28973620 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided warfarin dosing
Number of subjects: 1650
Study 28973620 — intervention group
Group type: COMPARATOR
Intervention: Clinically guided warfarin dosing
Number of subjects: 1650
Study 26025335 — intervention group
Group type: EXPERIMENTAL
Intervention: S + V (cycle sprints plus an aggressive video)
Number of subjects: 24
Study 26025335 — intervention group
Group type: EXPERIMENTAL
Intervention: V + S (aggressive video plus cycle sprints)
Number of subjects: 24
Study 26025335 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 24
Study 23537721 — intervention group
Group type: EXPERIMENTAL
Intervention: rIX-FP (25 IU/kg) on-demand therapy for 20 weeks
Number of subjects: 17
Study 23537721 — intervention group
Group type: EXPERIMENTAL
Intervention: rIX-FP (25 IU/kg) weekly prophylaxis for up to 44 weeks
Number of subjects: 17
Study 21147514 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 Gy radiotherapy
Number of subjects: 306
Study 21147514 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 Gy radiotherapy
Number of subjects: 306
Study 21147514 — intervention group
Group type: COMPARATOR
Intervention: Quality of life assessment
Number of subjects: 306
Study 19950570 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM sequential (TAM_SEQ)
Number of subjects: 163
Study 19950570 — intervention group
Group type: COMPARATOR
Intervention: TAM concurrent (TAM_CON)
Number of subjects: 163
Study 19950570 — intervention group
Group type: EXPERIMENTAL
Intervention: AI sequential (AI_SEQ)
Number of subjects: 163
Study 19950570 — intervention group
Group type: COMPARATOR
Intervention: AI concurrent (AI_CON)
Number of subjects: 163
Study 17300863 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta(1a) (Rebif, Serono) subcutaneous injections three times a week (group A)
Number of subjects: 25
Study 17300863 — intervention group
Group type: COMPARATOR
Intervention: Not receiving disease-modifying treatment (group B)
Number of subjects: 25
Study 16437737 — intervention group
Group type: EXPERIMENTAL
Intervention: Chan‐Chuang qigong
Number of subjects: 67
Study 16437737 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 12554614 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition
Number of subjects: 64
Study 12554614 — intervention group
Group type: COMPARATOR
Intervention: Sober condition
Number of subjects: 64
Study 12554614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intoxicated participants
Number of subjects: 64
Study 12554614 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in systolic blood pressure
Number of subjects: 64
Study 10983671 — intervention group
Group type: EXPERIMENTAL
Intervention: E/A ratio
Number of subjects: 19
Study 10983671 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial to total mitral annulus motion (AC)
Number of subjects: 19
Study 10983671 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal longitudinal LV relaxation velocity (RVm)
Number of subjects: 19
Study 10983671 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study 8857018 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 plus antiretroviral therapy
Number of subjects: 60
Study 8857018 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy alone
Number of subjects: 60
Study 1298048 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated injections of ranitidine, 50 mg every 6 h (group A)
Number of subjects: 18
Study 1298048 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ranitidine, 50-mg bolus followed by 0.125 mg/kg/h (group B)
Number of subjects: 18
Study 6326014 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonidamine alone
Number of subjects: 16
Study 6326014 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonidamine in combination with other anticancer agents
Number of subjects: 16
Study 31832719 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (Nicorette gum, 6mg)
Number of subjects: 0
Study 31832719 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 0
Study 31145689 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg) with piperine (5 mg)
Number of subjects: 55
Study 31145689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 28462892 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 3.0mg
Number of subjects: 4577
Study 28462892 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 4577
Study 25316484 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonobese women
Number of subjects: 182
Study 25316484 — intervention group
Group type: COMPARATOR
Intervention: Obese women
Number of subjects: 182
Study 25316484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 182
Study 23311678 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified activation method (6-month intervention)
Number of subjects: 1500
Study 23311678 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1500
Study 21844746 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent pelvic inflammatory disease
Number of subjects: 0
Study 21844746 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent sexually transmitted infection
Number of subjects: 0
Study 18488813 — intervention group
Group type: EXPERIMENTAL
Intervention: Adcef Suspension (125 mg/5 ml cefdinir)
Number of subjects: 24
Study 18488813 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (125 mg/5 ml cefdinir)
Number of subjects: 24
Study 17109346 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated rotavirus vaccine candidate 89-12
Number of subjects: 0
Study 17109346 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotarix vaccine developed from attenuated 89-12
Number of subjects: 0
Study 15235312 — intervention group
Group type: EXPERIMENTAL
Intervention: Valtrex treatment
Number of subjects: 20
Study 15235312 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 11765590 — intervention group
Group type: EXPERIMENTAL
Intervention: lysine clonixinate (125 mg five times a day for 3 days before and 13 days after ingestion of a single dose of phenprocoumon)
Number of subjects: 12
Study 11765590 — intervention group
Group type: COMPARATOR
Intervention: phenprocoumon (18 mg)
Number of subjects: 12
Study 9253919 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed bone-grafting technique
Number of subjects: 40
Study 9253919 — intervention group
Group type: COMPARATOR
Intervention: Open bone-grafting technique
Number of subjects: 40
Study 8515822 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.4 mg s.c.)
Number of subjects: 16
Study 8515822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline s.c.)
Number of subjects: 16
Study 3103932 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM
Number of subjects: 46
Study 3103932 — intervention group
Group type: COMPARATOR
Intervention: 5-FU plus BCNU
Number of subjects: 46
Study 3103932 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 46
Study 3103932 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SD
Number of subjects: 46
Study 3103932 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PD
Number of subjects: 46
Study 3103932 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with unmeasurable disease
Number of subjects: 46
Study 29436564 — intervention group
Group type: EXPERIMENTAL
Intervention: Celery leaf extract (250 mg, 3 times per day for 12 days)
Number of subjects: 16
Study 27693990 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar Taping (based in McConnell)
Number of subjects: 40
Study 27693990 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vertical taping on patella without any stretching of lateral structures of the knee)
Number of subjects: 40
Study 27693990 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Patellar Taping and Placebo)
Number of subjects: 40
Study 25325506 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face (F2F) recruitment from sleep clinics
Number of subjects: 148
Study 25325506 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face (F2F) recruitment from cardiology clinics
Number of subjects: 148
Study 25325506 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-based recruitment (MBR) from cardiology clinics
Number of subjects: 148
Study 23389964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for OCD
Number of subjects: 46
Study 23389964 — intervention group
Group type: COMPARATOR
Intervention: Anxiety Management (AM)
Number of subjects: 46
Study 20613468 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (6 microg/ml) via plasma target‐controlled infusion using the Schnider model
Number of subjects: 16
Study 19034030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 16
Study 19034030 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 16
Study 16704094 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1% sodium fluoride and acidulated phosphate gel
Number of subjects: 86
Study 16704094 — intervention group
Group type: COMPARATOR
Intervention: 0.243% sodium fluoride in a silica base
Number of subjects: 86
Study 14517525 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (n=79)
Number of subjects: 252
Study 14517525 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial intervention (n=71)
Number of subjects: 252
Study 14517525 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (n=102)
Number of subjects: 252
Study 10775074 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir prophylaxis
Number of subjects: 8
Study 10775074 — intervention group
Group type: COMPARATOR
Intervention: VZIG prophylaxis alone (Control)
Number of subjects: 8
Study 8990355 — intervention group
Group type: EXPERIMENTAL
Intervention: MeCsA
Number of subjects: 1097
Study 8990355 — intervention group
Group type: COMPARATOR
Intervention: ConCsA
Number of subjects: 1097
Study 1637603 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-stat group
Number of subjects: 65
Study 1637603 — intervention group
Group type: COMPARATOR
Intervention: alpha-stat group
Number of subjects: 65
Study 6711725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium, high-potassium diet with KCl salt substitute
Number of subjects: 69
Study 6711725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium, high-potassium diet without KCl salt substitute
Number of subjects: 69
Study 6711725 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 69
Study 30857431 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted, personalized risk information intervention
Number of subjects: 0
Study 30857431 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 30051368 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor location-modified Lauren classification (mLC)
Number of subjects: 2764
Study 30051368 — intervention group
Group type: COMPARATOR
Intervention: Lauren classification (LC)
Number of subjects: 2764
Study 30051368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on mLC
Number of subjects: 2764
Study 26004421 — intervention group
Group type: EXPERIMENTAL
Intervention: CIRCuiTS (Computerized Cognitive Remediation Therapy Programme)
Number of subjects: 59
Study 26004421 — intervention group
Group type: EXPERIMENTAL
Intervention: CIRCuiTS
Number of subjects: 59
Study 24164640 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler echocardiography (DE) and three-dimensional echocardiography (3DE) for AV- and VV-interval optimization (group 1, n = 39)
Number of subjects: 77
Study 24164640 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrocardiogram (ECG) optimization (group 2, n = 38)
Number of subjects: 77
Study 22759830 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma eyedrops along with standard medical treatment
Number of subjects: 20
Study 22759830 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment alone
Number of subjects: 20
Study 20096936 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine (10mg BID on day 1, 5 or 10mg BID thereafter)
Number of subjects: 185
Study 20096936 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (15 mg QD on day 1, 5-20mg QD thereafter)
Number of subjects: 185
Study 20096936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 20096936 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 185
Study 20096936 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 185
Study 18703470 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI plus optimal medical therapy
Number of subjects: 2287
Study 18703470 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 2287
Study 18703470 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2287
Study 15658966 — intervention group
Group type: EXPERIMENTAL
Intervention: Webster-Stratton Parenting Programme
Number of subjects: 0
Study 12558710 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rehydration
Number of subjects: 96
Study 12558710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) rehydration
Number of subjects: 96
Study 12558710 — intervention group
Group type: COMPARATOR
Intervention: IV/SC subgroup (patients who changed from IV to SC)
Number of subjects: 96
Study 12558710 — intervention group
Group type: COMPARATOR
Intervention: SC/IV subgroup (patients who changed from SC to IV)
Number of subjects: 96
Study 12558710 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SC and IV methods
Number of subjects: 96
Study 10677386 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide infusion at 3 pmol.min(‐1).kg(‐1) for 60 min and then at 10 pmol.min(‐1).kg(‐1) for 60 min
Number of subjects: 10
Study 10677386 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide infusion
Number of subjects: 10
Study 10677386 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10
Study 8931848 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin retard (12 mg)
Number of subjects: 185
Study 8931848 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin retard (4 mg)
Number of subjects: 185
Study 8931848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 1415970 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated neutral phrases including the colour orange
Number of subjects: 80
Study 1415970 — intervention group
Group type: COMPARATOR
Intervention: Repeated neutral phrases including the colour green
Number of subjects: 80
Study 3893286 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment plus thymostimulin
Number of subjects: 30
Study 3893286 — intervention group
Group type: COMPARATOR
Intervention: Local treatment plus placebo (control group)
Number of subjects: 30
Study 31388739 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina (4.8 g daily for 17 days)
Number of subjects: 35
Study 31388739 — intervention group
Group type: EXPERIMENTAL
Intervention: Wakame (4.8 g daily for 17 days)
Number of subjects: 35
Study 31388739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 29317001 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-Based Learning (VBL)
Number of subjects: 26
Study 29317001 — intervention group
Group type: COMPARATOR
Intervention: Traditional Lecture (TL)
Number of subjects: 26
Study 28002316 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pregabalin 150 mg and intravenous normal saline (group HP)
Number of subjects: 120
Study 28002316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 40 mg (group L)
Number of subjects: 120
Study 28002316 — intervention group
Group type: COMPARATOR
Intervention: Oral pregabalin 75 mg and intravenous normal saline (group LP)
Number of subjects: 120
Study 24231639 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake (≥ 4.6 g · kg(‐1) · day(‐1))
Number of subjects: 56
Study 24231639 — intervention group
Group type: EXPERIMENTAL
Intervention: Average protein intake of 4.3 ± 0.4 g · kg(‐1) · day(‐1)
Number of subjects: 56
Study 24231639 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein group (4.6 to 5.5 g · kg(‐1) · day(‐1), n = 16)
Number of subjects: 56
Study 24231639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative total kilocalories and protein
Number of subjects: 56
Study 23326930 — intervention group
Group type: EXPERIMENTAL
Intervention: Test treatment (nutriological combination of vitamins, trace elements, and phytochemicals)
Number of subjects: 100
Study 23326930 — intervention group
Group type: EXPERIMENTAL
Intervention: Test treatment
Number of subjects: 100
Study 23326930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 20615100 — intervention group
Group type: EXPERIMENTAL
Intervention: GLIM + PIO combination (up-titration 2 mg + 30 mg/4 mg + 30 mg/4 mg + 4 mg)
Number of subjects: 82
Study 20615100 — intervention group
Group type: COMPARATOR
Intervention: GLIM (up-titration 4/5/6 mg)
Number of subjects: 82
Study 18341414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 40
Study 18341414 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 40
Study 15723969 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 to 16 mg per day)
Number of subjects: 15
Study 15723969 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 to 20 mg per day)
Number of subjects: 15
Study 12689739 — intervention group
Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 0
Study 12689739 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic diary with compliance-enhancing features
Number of subjects: 0
Study 12870993 — intervention group
Group type: EXPERIMENTAL
Intervention: DHE focused on diet
Number of subjects: 228
Study 12870993 — intervention group
Group type: EXPERIMENTAL
Intervention: DHE focused on oral hygiene instruction (OHI) using fluoride toothpaste
Number of subjects: 228
Study 12870993 — intervention group
Group type: EXPERIMENTAL
Intervention: DHE by a combined diet and OHI message
Number of subjects: 228
Study 12870993 — intervention group
Group type: EXPERIMENTAL
Intervention: DHE given once a year
Number of subjects: 228
Study 12870993 — intervention group
Group type: COMPARATOR
Intervention: Control group (E) with no DHE
Number of subjects: 228
Study 9690309 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy containing platinum
Number of subjects: 0
Study 9690309 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy using alkylating agents
Number of subjects: 0
Study 9690309 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with Cisplatin
Number of subjects: 0
Study 9690309 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant radiotherapy and chemotherapy using 5-Fluoro-uracil, VP16, and platinum
Number of subjects: 0
Study 9690309 — intervention group
Group type: EXPERIMENTAL
Intervention: Short initial chemotherapy or concomitant therapy
Number of subjects: 0
Study 9690309 — intervention group
Group type: EXPERIMENTAL
Intervention: Short neoadjuvant chemotherapy to surgery
Number of subjects: 0
Study 7853038 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analytic methods for diagnostic test accuracy
Number of subjects: 0
Study 7853038 — intervention group
Group type: EXPERIMENTAL
Intervention: Moses et al. method for estimating Summary Receiver Operating Characteristic Curves
Number of subjects: 0
Study 7853038 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods for analysing multi-category and continuous test data
Number of subjects: 0
Study 2345633 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (Legalon) therapy at a daily dose of 420 mg for six months
Number of subjects: 0
Study 2345633 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 378199 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 14
Study 378199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6303490 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg intramuscularly
Number of subjects: 128
Study 6303490 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin 2 g intramuscularly with oral probenecid 1 g
Number of subjects: 128
Study 26803355 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide supplementation on glargine insulin (group B)
Number of subjects: 110
Study 26803355 — intervention group
Group type: COMPARATOR
Intervention: Intense, self-regulated insulin therapy alone (group C)
Number of subjects: 110
Study 25539976 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured transition approach integrating Berliner TransitionsProgramm and two smartphone apps
Number of subjects: 17
Study 25539976 — intervention group
Group type: COMPARATOR
Intervention: Current unstructured transition (control group)
Number of subjects: 17